x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:22:13

Solid Biosciences CEO Bo Cumo discusses recent DMD...

BiotechTV - News ·

2026/03/25

He describes data presented at the Muscular Dystophy Association Annual Meeting which showed biopsy and safety data for 20 patients who have been followed for 90 days and 3 who are out to a year. Plus, explaining the three FDA meetings that are key ffor the company.

en-us

00:06:57

Christian Tidona's BioMed X and Michal Preminger are...

BiotechTV - News ·

2026/03/25

Michal Preminger will lead BioMed X Venture labs as CEO, and it will partner with pharma, foundations, and VCs to build mission driven companies.

en-us

00:10:23

Apogee Therapeutics' CEO Michael Henderson discusses...

BiotechTV - News ·

2026/03/23

He discusses the the data and how he compares it to Dupixent and other medicines on the market, how translatable the data might be to a phase 3 that will be up and running later this year, and what other data the company will have in the near future.

en-us

00:39:47

Biotech CEOs discuss the importance of culture,...

BiotechTV - News ·

2026/03/20

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Zag Bio CEO Jason Cole and Altido Therapeutics CEO Chip Clark about running early stage companies and what advice they have for new CEOs. They offer advice about what it will take to keep our ecosystem globally competitive.

en-us

00:09:49

From London: Yellowstone Biosciences is leveraging an...

BiotechTV - News ·

2026/03/20

From Syncona's Capital Markets Day, CEO Jim MacDonald describes the learnings Yellowstone has gained from looking at cured AML patients from the Oxford biobank and how it is translating that into new medicines.

en-us

00:10:35

From London: Edward Hodgkin is the Executive Chair of...

BiotechTV - News ·

2026/03/20

From Syncona's Capital Markets Day, he describes Slingshot and how he believes it differs from other early stage VC investors. Once an asset is ready for the clinic, Slingshot will either partner it or build its own company.

en-us

00:11:21

From London: Purespring Therapeutics is developing a...

BiotechTV - News ·

2026/03/20

From Syncona's Capital Markets Day, CEO Haseeb Ahmed describes the science behind the platform, and make the case why IgAN, a condition that has seen a bevy of new therapies in development, is the right indication for a gene therapy.

en-us

00:14:35

From London: Resolution Therapeutics is in the clinic...

BiotechTV - News ·

2026/03/19

CEO Amir Hefni describes the ability of macrophages to reduce inflammation and reverse fibrosis in conditions like liver disease. An interim analysis for the clinical trial will read later this year.

en-us

00:11:34

From London: With science from the Francis Crick...

BiotechTV - News ·

2026/03/19

From Syncona's Capital Markets Day, ALTx founder and Francis Crick researcher Simon Boulton describes ALTs and the science behind how the company plans to target them.

en-us

00:11:54

From London: iOnctura is developing its allosteric...

BiotechTV - News ·

2026/03/19

From Syncona's Capital Markets Day, Founder and CEO Catherine Pickering walks us through the science of roginolisib and describes the current landscape for uveal melanoma. She discusses her phase 2, which is approaching a key readout.

en-us

00:13:33

From London: Spur Therapeutics is an a phase 3 for...

BiotechTV - News ·

2026/03/19

CEO Michael Parini describes the science behind how Spur's gene therapies have two key differences compared to others, including a proprietary capsid. He discusses phase 1/2 data that has already been announced, and how he thinks about the phase 3.

en-us

00:08:22

From London: Beacon Therapeutics has a phase 3 trial...

BiotechTV - News ·

2026/03/19

From Syncona's Capital Markets Day, CEO Lance Baldo describes the trial's design and the degree to which Beacon will be trying to restore vision for these patients.

en-us

00:17:52

From London: Syncona CEO Chris Hollowood discusses...

BiotechTV - News ·

2026/03/19

He talks about Syncona's listed fund, and clarifies the details of a return of capital strategy for some shareholders, and he describes the strategy of the firm's new private fund. Plus, how Syncona thinks about opportunities in life sciences today.

en-us

00:18:03

Checking in with Menlo Ventures' Partner Greg Yap to...

BiotechTV - News ·

2026/03/18

He his take on topics such as how the Baby KJ news is allowing investors and companies to think about scaling bespoke therapies, how AI might start to impact the clinical trial side of our business, and why he sees pharma adoption of AI as being important.

en-us

00:21:57

Earli, which raised $105M in two rounds, is...

BiotechTV - News ·

2026/03/17

Co-Founder & CEO Cyriac Roeding and Co-Founder & CSO David Suhy describe the science behind this approach and explain how AI is helping they move closer to the clinic. The first IND filing is scheduled to be late '26 or early '27.

en-us

00:14:09

Barclays Miami: MannKind CEO Michael Castagna shares...

BiotechTV - News ·

2026/03/11

He describes learnings from Afrezza's commercialization, why the company acquired scPharmaceuticals, an update on their partnership with United Therapeutics in PAH, and a key IPF asset that is in the pipeline.

en-us

00:14:03

Barclays Miami: Barclays' Senior Biotech Analyst...

BiotechTV - News ·

2026/03/11

He comments on Abivax, Corvus, Iovance, Legend, Terns, and more.

en-us

00:12:13

Barclays Miami: Zealand Pharma CEO Adam Steensberg...

BiotechTV - News ·

2026/03/11

He argues that investors are too focused on each percentage of weight loss and not focused enough on the tolerability of new options. He discusses the timeline for the phase 3 that will likely start later this year, and how it might look different than the phase 2 study that just read out.

en-us

00:05:35

Barclays Miami: Barclays' Head of Healthcare M&A...

BiotechTV - News ·

2026/03/11

Maneet Singh says that pharma companies need to keep buying, and have the financial wherewithal to do it. He also gives thoughts on which areas within biotech could attract the most interest.

en-us

00:11:47

Reunion Neuroscience recently received Breakthrough...

BiotechTV - News ·

2026/03/11

CEO Greg Mayes describes the science behind luvesilocin, which is a prodrug of 4-OH-DiPT, a psilocybin-like compound, and discusses the company's plans for a phase 3 study. Plus, comments on two other indications the company is pursuing.

en-us

408 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter